Moreover, proteomic analysis of samples derived from patients with stage III skin melanoma (according to the 7th edition of AJCC staging) revealed that elevated PARP1 expression might be one of the markers discriminating patients with better prognosis from those with the worse one [40]. This evidence concerns the gene PARP1 and cutaneous melanoma.